Lipid Manager7.9

The ACC Lipid Manager app provides two clinical decision support tools in one app to help clinicians manage a patient’s triglycerides and LDL-C from therapy initiation through treatment calibration with the goal of lowering ASCVD risk:
.  Lipid Lowering Therapy tool: Supports selection of lipid‑lowering therapies and individualized goals to reduce ASCVD risk through targeted management of LDL-C and triglycerides (previously known as LDL-C Lowering Therapy)
.  Statin Intolerance tool: Evaluate the patient for possible statin intolerance, and determine appropriate next steps

The information and recommendations in this clinical decision support app are not meant to represent the only or best course of care nor replace clinical judgement. Therapeutic options should be determined after discussion between the patient and their care provider.
Financial support for Lipid Manager was provided by Esperion. All content was independently developed with no sponsor involvement.

Version History The Hypertriglyceridemia tool has been merged into the newly-renamed Lipid Lowering Therapy tool and now includes recommendations for the management of hypertriglyceridemia in accordance with the 2026 ACC/AHA Guideline on the Management of Dyslipidemia. 7.9 Jun 12 Bug fixes and functionality enhancement. 7.3 May 16 This app has been updated in accordance with the 2026 ACC/AHA Guideline on the Management of Dyslipidemia and now utilizes the American Heart Association’s PREVENT™-ASCVD risk estimator as part of the evaluation process. This update includes the latest evaluation workflows and advice for lipid lowering therapy within the LDL-C Lowering Therapy and Statin Intolerance tools. 7.2 May 12 Adding temporary disclaimer. 6.5 Mar 13 Bug fixes 6.4 09/16/2025 Bug fix 6.3 03/07/2024 Bug fixes 6.2 12/19/2023 New content from the Standards for Adult Immunization Practice has been incorporated into the Lipid Manager app. 6.1 09/01/2023 This update includes underlying architecture improvements and minor reference link updates. 6.0 08/12/2023 This app has been updated in accordance with the 2022 ACC ECDP on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of ASCVD Risk to incorporate newer nonstatin agents, such as bempedoic acid, evinacumab, and inclisiran. This update also includes improved risk discrimination in patient evaluation, now incorporating CAC scoring, evidence of subclinical atherosclerosis, and Familial Hypercholesterolemia. 4.1 02/03/2023 The app name has changed from LDL-C Manager to Lipid Manager and added the new tool Hypertriglyceridemia. 4.0 03/16/2022 Updated advice content and resources based on the 2018 ACC/AHA et al. Guideline on the Management of Blood Cholesterol 2.1 11/10/2018 Updated content based on recent clinical trials, including FOURIER 2.0 11/15/2017 • Incorporates Statin Intolerance as an in-app tool
• Typo fixes
• Bug fixes 1.1 05/22/2017 1.0 02/21/2017